Health innovation with future potential

Last Updated: 29. Januar 2024By

In the exciting world of medical technology, we take a look at two promising stocks today that represent groundbreaking innovations and strong growth potential in the healthcare industry.

RadNet revolutionizes diagnostics with AI The American company RadNet (ISIN: US7504911022; abbreviation: RDNT) is a leading provider of outpatient diagnostic imaging with 366 locations in the USA. The company offers a wide range of radiological services, including MRI, CT, ultrasound, X-ray, and mammography. The market for outpatient diagnostic imaging is large and growing steadily. In the USA, the market is estimated at over 100 billion USD. RadNet addresses a significant portion of this market.

In recent years, RadNet has implemented a number of growth initiatives, including acquisitions, partnerships, and expanding its service offerings.

One of RadNet’s most important growth initiatives is investing in artificial intelligence (AI). The company has acquired three AI companies in recent years: DeepHealth, Aidence, and Quantib, making it a hidden AI profiteer.

RadNet’s AI solutions are used for early cancer detection, improving diagnostic accuracy, and increasing efficiency in radiology. RadNet’s AI revenues tripled in 2023 and are expected to continue to grow strongly in the coming years. Management expects AI revenues to reach 20 to 25 million USD in 2024.

RadNet is a leading provider of outpatient diagnostic imaging with strong growth potential. Investments in artificial intelligence could make the company one of the leading AI companies in the healthcare sector.

RadNet’s stock has performed well in recent months. The company is well positioned to benefit from trends in the healthcare sector. The stock could be an interesting investment for investors looking for growth stocks.

Carl Zeiss Meditec maintains a clear view In the next 35 years, half of the world’s population will be nearsighted and will need glasses, with one billion people potentially going almost blind by 2050. Carl Zeiss Meditec AG (ISIN: DE0005313704), a company based in Jena and owned by the Carl Zeiss Foundation, is facing accelerated growth. The company is a leading player in medical technology and offers comprehensive solutions for the diagnosis and treatment of eye diseases, as well as innovative visualization solutions for microsurgery, including intraoperative radiotherapy.

The company is known for its leading role in the treatment of eye diseases, especially for the development of the eye laser „Lasik“ and its further development „SMILE“. With „Lasik 2.0“ and „SMILE“, the company is facing a gamechanger that is expected to further boost its business, especially in Asia, where these technologies are just starting to be used in clinics and practices. The new technologies offer shorter procedure times, lower risk of infection, faster healing, and less frequent side effects. Carl Zeiss Meditec is far ahead of its competition, including Johnson & Johnson and Alcon, and has given up in some areas.

The company is expanding its market presence internationally, especially in China, Asia, and the Arab world, through strategic acquisitions and the development of the national healthcare system. In recent years, it has increased its market share in refractive laser treatment and is now targeting the market for cataract treatment, which is four times larger than previous segments.

Forecasts for 2023/24 already exceed market expectations and could lead to a halving of the P/E ratio to 22 within three years. Although Carl Zeiss Meditec has a stable revenue and earnings, there is expected to be a dynamic that could significantly increase the company’s market value.